New combo aims to wipe out breast cancer before surgery
NCT ID NCT07102940
First seen Nov 01, 2025 · Last updated May 11, 2026 · Updated 21 times
Summary
This study tests whether adding an immune-boosting drug (eftilagimod alpha) to standard chemotherapy before surgery can eliminate more breast cancer in people with early-stage HR+/HER2- breast cancer. About 50 participants will receive the drug combination, and researchers will check how many have no cancer left in the surgical sample. The goal is to improve current treatment outcomes for this common breast cancer type.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.